News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,982 Results
Type
Article (14345)
Company Profile (105)
Press Release (260524)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88535)
Career Advice (466)
Deals (15467)
Drug Delivery (73)
Drug Development (36868)
Employer Resources (50)
FDA (6403)
Job Trends (6254)
News (151207)
Policy (14170)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (445)
Accelerated approval (13)
Adcomms (8)
Allergies (69)
Alliances (23391)
ALS (56)
Alzheimer's disease (483)
Antibody-drug conjugate (ADC) (99)
Approvals (6593)
Artificial intelligence (202)
Autoimmune disease (43)
Automation (12)
Bankruptcy (153)
Best Places to Work (4385)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (172)
Cancer (1324)
Cardiovascular disease (152)
Career advice (419)
Career pathing (13)
CAR-T (51)
CDC (6)
Cell therapy (153)
Cervical cancer (9)
Clinical research (32161)
Collaboration (736)
Compensation (326)
Complete response letters (33)
COVID-19 (780)
CRISPR (43)
C-suite (440)
Cystic fibrosis (58)
Data (1842)
Denatured (18)
Depression (45)
Diabetes (127)
Diagnostics (1393)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (117)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (81)
Earnings (33549)
Editorial (20)
Employer branding (4)
Employer resources (46)
Events (39123)
Executive appointments (533)
FDA (7512)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (445)
Gene editing (70)
Generative AI (18)
Gene therapy (171)
GLP-1 (443)
Government (1407)
Grass and pollen (4)
Guidances (164)
Healthcare (3591)
HIV (12)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (69)
Immuno-oncology (15)
Indications (54)
Infectious disease (844)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (114)
Interviews (60)
IPO (5958)
IRA (33)
Job creations (2063)
Job search strategy (375)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3453)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (417)
MASH (67)
Medical device (1324)
Medtech (1331)
Mergers & acquisitions (9930)
Metabolic disorders (439)
Multiple sclerosis (48)
NASH (14)
Neurodegenerative disease (83)
Neuropsychiatric disorders (37)
Neuroscience (895)
Neurotech (1)
NextGen: Class of 2026 (1603)
Non-profit (602)
Now hiring (17)
Obesity (231)
Opinion (141)
Ovarian cancer (40)
Pain (111)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (222)
Patient recruitment (116)
Peanut (12)
People (29821)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8342)
Phase 2 (13599)
Phase 3 (12251)
Pipeline (1948)
Policy (135)
Postmarket research (1402)
Preclinical (3356)
Press Release (25)
Prostate cancer (85)
Psychedelics (16)
Radiopharmaceuticals (136)
Rare diseases (353)
Real estate (2669)
Recruiting (19)
Regulatory (11002)
Reports (15)
Research institute (579)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (81)
Series B (58)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1677)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (235)
Venture capital (33)
Weight loss (142)
Women's health (28)
Worklife (4)
Date
Today (54)
Last 7 days (188)
Last 30 days (734)
Last 365 days (10478)
2026 (1037)
2025 (10745)
2024 (12548)
2023 (14312)
2022 (19597)
2021 (20119)
2020 (19092)
2019 (14952)
2018 (11786)
2017 (13929)
2016 (13168)
2015 (15519)
2014 (12474)
2013 (10676)
2012 (11493)
2011 (12033)
2010 (10962)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20941)
Australia (2688)
California (3205)
Canada (1490)
China (555)
Colorado (144)
Connecticut (129)
Delaware (124)
Europe (40958)
Florida (603)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (350)
India (45)
Indiana (242)
Iowa (2)
Japan (249)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (425)
Massachusetts (2612)
Michigan (47)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1401)
New Mexico (7)
New York (911)
North Carolina (624)
North Dakota (2)
Northern California (1466)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (722)
Puerto Rico (13)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1395)
Tennessee (53)
Texas (459)
United States (12763)
Utah (60)
Virginia (161)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (38)
Wyoming (1)
274,982 Results for "polaris pharmaceuticals inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
KHB Highlights the Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer at MEDICA 2025
November 19, 2025
·
4 min read
Press Releases
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
November 4, 2025
·
15 min read
Press Releases
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
December 9, 2025
·
11 min read
Press Releases
Er-Kim Announces Exclusive Distribution Agreement with Polaris Pharmaceuticals to Commercialize Pegargiminase (ADZODI) for Malignant Pleural Mesothelioma (MPM) in Multiple EMEA Markets
April 16, 2025
·
3 min read
Drug Development
AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
AriBio Co., Ltd. announced authorisation from the European Medicines Agency for POLARIS-AD, a global, phase 3, early Alzheimer’s disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency on the Clinical Trial Authorisation of POLARIS-AD.
April 28, 2024
·
3 min read
Press Releases
HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
July 23, 2025
·
4 min read
Drug Development
AriBio Receives IND Approval from China’s NMPA for POLARIS-AD, a Phase 3 Trial for the Treatment of Early Alzheimer’s Disease
AriBio Co., Ltd. (AriBio) announces approval of the Investigational New Drug (IND) application by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the initiation of the Phase 3 Polaris-AD trial in China of AR1001 in early Alzheimer’s Disease (AD) on May 11th, 2024.
May 14, 2024
·
3 min read
Drug Development
MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.
AriBio Co., Ltd. receives Notice of Acceptance for POLARIS-AD, a Phase 3 early Alzheimer’s disease clinical trial from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom.
February 25, 2024
·
2 min read
Deals
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth
Polaris Group announced that its board approved to increase the acquisition of Genovior Biotech’s shares to 100%.
December 21, 2023
·
3 min read
Drug Development
AriBio Co., Ltd. Announces Global Expansion of POLARIS-AD, A Phase 3 Early Alzheimer’s Disease Registration Trial
AriBio Co., Ltd. announces the global expansion of the POLARIS-AD study, a phase 3 early Alzheimer’s disease trial into the European Union, United Kingdom, Korea and China.
November 14, 2023
·
3 min read
1 of 27,499
Next
